- Home
- SKM vs BBIO Comparison
SKM vs BBIO Comparison
Compare SKM & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKM | BBIO |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 12.7B |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SKM | BBIO |
|---|---|---|
| Price | $33.38 | $68.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 25 |
| Target Price | N/A | ★ $86.33 |
| AVG Volume (30 Days) | ★ 3.0M | 2.7M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $4.41 | $89.45 |
| Revenue Next Year | $1.85 | $73.78 |
| P/E Ratio | $31.64 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $19.66 | $41.80 |
| 52 Week High | $47.18 | $84.94 |
Technical Indicators
Market Signals| Indicator | SKM | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.57 | 53.62 |
| Support Level | $28.06 | $67.57 |
| Resistance Level | $40.23 | $69.78 |
| Average True Range (ATR) | 1.63 | 2.50 |
| MACD | -0.81 | 0.33 |
| Stochastic Oscillator | 8.04 | 85.26 |
Price Performance
Historical ComparisonAbout SKM SK Telecom Co. Ltd.
SK Telecom is South Korea's largest wireless telecom operator, with 32 million mobile customers. The firm also owns SK Broadband (formerly Hanaro Telecom), which has 7.2 million broadband customers and 9.5 million pay TV customers (6.7 million IPTV and 2.8 million Cable TV). While the firm also purchased stakes in businesses in security and semiconductor memory production as well as developing e-commerce and internet platform businesses, these were all spun off into the separate, SK Square business in November 2021. The company was formed after SK Group purchased KT's mobile business in 1994.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.